Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study
作者: Eun Ha KangYinzhu JinRishi J. DesaiJun LiuJeffrey A. SparksSeoyoung C. Kim
作者单位: 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
2Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
刊名: Seminars in Arthritis and Rheumatism, 2019
来源数据库: Elsevier Journal
DOI: 10.1016/j.semarthrit.2019.11.010
关键词: Rheumatoid arthritisPulmonary comorbidityInterstitial lung diseaseChronic obstructive pulmonary diseaseAsthmaComparative effectiveness researchBiologic DMARD
原始语种摘要: Abstract(#br)Background(#br)Biologic agents may pose a potential risk for exacerbations of pulmonary comorbidities in rheumatoid arthritis (RA) patients.(#br)Methods(#br)Using U.S. Medicare and Truven MarketScan databases, we identified three cohorts of RA patients with interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD), or asthma who initiated abatacept or a TNF inhibitor (TNFi). The primary outcome was a composite exacerbation of individual pulmonary comorbidities based on inpatient or emergency department (ED) visits due to exacerbation of the given pulmonary comorbidity. To adjust for >60 baseline confounders, we used propensity-score fine stratification (PSS) and weighting. Negative binomial regression model estimated a cohort-specific incidence rate ratio...
全文获取路径: Elsevier  (合作)
影响因子:3.806 (2012)

  • exacerbation 恶化
  • arthritis 关节炎
  • pulmonary 肺的
  • rheumatoid 患风湿病的
  • cohort 伙伴
  • asthma 哮喘
  • obstructive 阻碍的
  • inpatient 住院病人
  • combined 组合
  • versus